What is GeniPhys?
GeniPhys operates at the intersection of material science and clinical healthcare, specializing in the development and commercialization of custom-designed collagen materials. The company's core technology facilitates the fabrication of scaffolds that support accelerated and improved tissue restoration and regeneration. By providing a versatile platform for medical professionals, GeniPhys addresses critical gaps in current surgical and therapeutic interventions.
The company's market position is defined by its ability to bridge the gap between laboratory-scale innovation and scalable clinical application. Based in Zionsville, Indiana, GeniPhys leverages regional expertise to refine its collagen-based products, which are engineered to mimic natural biological structures. This focus on high-fidelity tissue regeneration positions the firm as a disruptive force in the broader medical technology landscape, offering potential improvements in patient outcomes across various surgical specialties.
How much funding has GeniPhys raised?
GeniPhys has raised a total of $9M across 2 funding rounds:
Series A
$6M
Stock/Share Issuance
$3M
Series A (2023): $6M with participation from Pier 70 Ventures and Elevate Ventures
Stock/Share Issuance (2026): $3M, investors not publicly disclosed
Key Investors in GeniPhys
Pier 70 Ventures
Pier 70 Ventures is an impact-driven investment firm that focuses on healthcare innovation and sustainable high-growth companies, providing both capital and mentorship.
Elevate Ventures
Elevate Ventures is a prominent Indiana-based investor that supports cross-sector innovation by providing funding and strategic guidance to early-stage companies.
Undisclosed Investors
What's next for GeniPhys?
With the recent influx of capital, GeniPhys is expected to prioritize the expansion of its manufacturing capabilities and the advancement of its regulatory milestones. The strategic focus will likely shift toward scaling production to meet anticipated clinical demand while simultaneously deepening its research and development pipeline for next-generation collagen applications.
As the company matures, the emphasis will remain on validating its technology through rigorous clinical data and establishing strategic partnerships within the healthcare ecosystem. By maintaining its trajectory of innovation, GeniPhys is poised to capture a larger share of the regenerative medicine market, ultimately aiming to set new standards for tissue repair and patient recovery protocols.
